Johan G
Brun
Adjunct Professor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 54 00
E-mail:
Journal articles
- 2014. The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab. BMC Musculoskeletal Disorders. 15: 335.
- 2014. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome. Scandinavian Journal of Rheumatology. 43: 76-78.
- 2014. A possible genetic association with chronic fatigue in primary Sjögren’s syndrome: a candidate gene study. Rheumatology International. 34: 191-197. doi: 10.1007/s00296-013-2850-9
- 2014. Genetic associations to germinal centre formation in primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 73: 1253-1258. doi: 10.1136/annrheumdis-2012-202500
- 2013. No association of primary Sjögren's syndrome with Fcγ receptor gene variants. Genes and Immunity. 14: 234-237. doi: 10.1038/gene.2013.12
- 2013. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care and Research. 65: 816-821. doi: 10.1002/acr.21887
- 2013. Carbamylation of immunoglobulin abrogates the classical pathway of complement activation. Immunology. 140: 76-76.
- 2013. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nature Genetics. 45: 1284-1292. doi: 10.1038/ng.2792
- 2013. Sjögrens syndrom -en oppdatering. Revmatologi BestPractice. 14. 18-21.
- 2013. Association of genes in the NF-kappa B pathway with antibody-positive Primary Sjögren's Syndrome. Scandinavian Journal of Immunology. 78: 447-454. doi: 10.1111/sji.12101
- 2013. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. Arthritis Research & Therapy. 15. 12 pages. doi: 10.1186/ar4294
- 2012. Evaluation of genetic association between an ITGAM non-synonymous SNP (rs1143679) and multiple autoimmune diseases. Autoimmunity Reviews. 11: 276-280. doi: 10.1016/j.autrev.2011.07.007
- 2012. Autoantigen-specific memory B cells in primary Sjögren's syndrome. Scandinavian Journal of Immunology. 75: 61-68. doi: 10.1111/j.1365-3083.2011.02625.x
- 2012. Association between genetic variants in the tumour necrosis factor/lymphotoxin alpha/lymphotoxin beta locus and primary Sjogren's syndrome in Scandinavian samples. Annals of the Rheumatic Diseases. 71: 981-988. doi: 10.1136/annrheumdis-2011-200446
- 2012. Large molecular size EDTA-resistant complexes containing S100A12, ERAC, in serum during inflammatory conditions. Scandinavian Journal of Clinical and Laboratory Investigation. 72: 129-136. doi: 10.3109/00365513.2011.643819
- 2012. No association of primary Sjögren's Syndrome with Fc gamma? Receptor gene variants. Scandinavian Journal of Immunology. 76: 198-198.
- 2012. The risk of Non-Hodgkin Lymphoma in Primary Sjögren's Syndrome, a population-based study. Arthritis Care and Research. doi: 10.1002/acr.21887
- 2012. Ultrasonography of Major Salivary Glands in Primary Sjogren's syndrome. Arthritis and Rheumatism. 64: S925-S925.
- 2012. Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study. Journal of Rheumatology. 39: 2008-2011. doi: 10.3899/jrheum.111549
- 2012. Validation of EULAR Primary Sjogren's Syndrome Disease Activity and Patient Indexes. Arthritis and Rheumatism. 64: S1078-S1078.
- 2011. Potential association of muscarinic receptor 3 gene variants with primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 70: 1327-1329. doi: 10.1136/ard.2010.138966
- 2011. The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian counties. Scandinavian Journal of Rheumatology. 40: 221-224. doi: 10.3109/03009742.2010.536164
- 2011. A five-year prospective study of fatigue in primary Sjögren’s syndrome. Arthritis Research & Therapy. 13. doi: 10.1186/ar3487
- 2011. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes and Immunity. 12: 100-109. doi: 10.1038/gene.2010.44
- 2011. Implications of long-term medication of oral steroids and antimalarial drugs in primary Sjögren's syndrome. International Immunopharmacology. 11: 2125-2129. doi: 10.1016/j.intimp.2011.09.006
- 2011. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Annals of the Rheumatic Diseases. 70: 968-972. doi: 10.1136/ard.2010.143743
- 2011. Phenotypic diversity of peripheral blood plasma cells in primary Sjögren’s Syndrome. Scandinavian Journal of Immunology. 73: 18-28. doi: 10.1111/j.1365-3083.2010.02475.x
- 2010. Patients with Primary Sjogren's Syndrome have Significantly Reduced Amounts of Plasmacytoid and Type 2 Myeloid Dendritic Cells in Peripheral Blood. Scandinavian Journal of Immunology. 71: 479-479.
- 2010. Association between Lymphotoxin Alpha Genetic Variants and Primary Sjögren`s Syndrome in Scandinavian Samples. Arthritis and Rheumatism. 62: 788-789.
- 2010. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 69: 1731-1732. doi: 10.1136/ard.2009.122903
- 2010. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren's syndrome. Annals of the Rheumatic Diseases. 69: 1731-1732. doi: 10.1136/ard.2009.122903
- 2010. Fc gamma receptor IIA, IIIA and IIIB single nucleotide polymorphisms and Fc gamma receptor IIIB copy number variation: No association with primary Sjögren's syndrome. Scandinavian Journal of Rheumatology. 39: 36-36.
- 2010. Prevalence of primary Sjogren's syndrome in two Norwegian counties. Scandinavian Journal of Rheumatology. 39: 36-36.
- 2010. Sjögren's Syndrome. Encyclopedia of Life Sciences. Published 2010-02-15. doi: 10.1002/9780470015902.a0002149.pub2
- 2010. MRI of the transverse and alar ligaments in rheumatoid arthritis: feasibility and relations to atlantoaxial subluxation and disease activity. Neuroradiology. 52: 215-223. doi: 10.1007/s00234-009-0650-4
- 2010. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 69: 1235-1238. doi: 10.1136/ard.2009.118158
- 2009. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes and Immunity. 10: 68-76. doi: 10.1038/gene.2008.94
- 2009. Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rhematology Int. 48: 1102-1106. doi: 10.1093/rheumatology/kep149
- 2008. Sjögrens syndrom. Norsk Epidemiologi. 18: 67-72.
- 2008. Association of BLK with Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE) initially identified by whole genome DNA pooling. Arthritis and Rheumatism. 58: S791-S791.
- 2008. Association of Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE) with BLK. Clinical Immunology. 127: S41-S41. doi: 10.1016/j.clim.2008.03.111
- 2008. Impact of lean mass and fat mass on bone mineral density: The Hordaland Health Study. Maturitas. 59: 191-200. doi: 10.1016/j.maturitas.2007.11.002
- 2008. Exocrine function in primary Sjogren syndrome: natural course and prognostic factors. Annals of the Rheumatic Diseases. 67: 949-954. doi: 10.1136/ard.2007.074203
- 2008. Estimation of the prevalence of primary Sjogren's syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scandinavian Journal of Rheumatology. 37: 30-34. doi: 10.1080/03009740701678712
- 2008. Histopathology in Seropositive Focus Score Negative Primary Sjögren’s Syndrome. Annals of the Rheumatic Diseases. 67: 470-470.
- 2008. Additive effects of the major risk Alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Arthritis and Rheumatism. 58: S430-S430.
- 2008. The complex role of vitamin D in autoimmune diseases. Scandinavian Journal of Immunology. 68: 261-269. doi: 10.1111/j.1365-3083.2008.02127.x
- 2008. Use of bladder capacity and uroflowmetry to elucidate lower urinary tract symptoms (LUTS) in primary Sjögren’s Syndrome (PSS). Annals of the Rheumatic Diseases. 67: 617-617.
- 2007. 257 ankle arthroplasties performed in Norway between 1994 and 2005. Acta Orthopaedica. 78: 575-583. doi: 10.1080/17453670710014257
- 2007. Serological Implications of Germinal Center-like structures in Primary Sjögren’s Syndrome. Journal of Rheumatology. 34: 2044-2049.
- 2007. Sjögren's syndrome - A plethora of clinical and immunological phenotypes with a complex genetic background. Annals of the New York Academy of Sciences. 1108: 433-447. doi: 10.1196/annals.1422.046
- 2007. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. Joint Bone Spine. 74: 606-611. doi: 10.1016/j.jbspin.2007.04.009
- 2007. S100 proteins calprotectin and S100A12 are related to radiological changes rather than disease activity in psoriatic arthritis. Annals of the Rheumatic Diseases. 66: 98.
- 2007. S100 proteins calprotectin and S100A12 are related to' radiographic changes rather than disease activity in psoriatic arthritis with low disease activity. Journal of Rheumatology. 34: 2089-2092.
- 2007. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rhematology Int. 46: 417-425. doi: 10.1093/rheumatology/kel306
- 2006. Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease. Lipids in Health and Disease. 5. doi: 10.1186/1476-511X-5-6
- 2006. Exocrine function in Sjogren's syndrome: Natural course and prognostic factors. Annals of the Rheumatic Diseases. 65.
- 2006. Intraepidermal nerve fiber densities in chronic inflammatory autoimmune diseases. Archives of Neurology. 63: 1410-1413.
- 2006. Germinal centers in primary Sjogren's syndrome indicate a certain clinical immunological phenotype. Scandinavian Journal of Rheumatology. 35: 21-22.
- 2006. Serum levels of soluble E-cadherin as an indicator of chronic inflammatory disease. Scandinavian Journal of Rheumatology. 35: 45-45.
- 2006. Anti TNF-alpha treatment of patients with rheumatoid arthritis.Outcome in an ordinary clinical setting. Scandinavian Journal of Rheumatology. Supplement. 35: 41-41.
- 2006. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. Journal of Rheumatology. 33: 307-310.
- 2006. Calprotectin and S100A12 correlate with disease activity in rheumatoid arthritis, and S100A12 is associated with concomitant cardiovascular disease. Scandinavian Journal of Rheumatology. 35: 40-40. doi: 10.1080/03009740601090836
- 2006. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of bacterial DNAs. Clinical and Experimental Rheumatology. 24: 656-663.
- 2006. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clinical and Experimental Rheumatology. 57-65.
- 2006. Polymyalgia rheumatica in primary Sjogren's syndrome. Rheumatology International. 26: 401-403. doi: 10.1007/s00296-005-0010-6
- 2005. Prevalence, Disease Manifestations and Treatment of Psoriatic Arthritis in Western Norway (County of Hordaland). Journal of Rheumatology. 32: 1918-1922.
- 2005. Salivary gland and temporomandibular joint involvement in rheumatoid arthritis: relation to disease activity. Oral Diseases. 11: 27-34.
- 2005. Oral bacterial DNAs in synovial fluids of arthritis patients. Microbial Ecology in Health and Disease. 17: 2-8. doi: 10.1080/08910600510031394
- 2005. The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: A pilot study. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 100: 433-440. doi: 10.1016/j.tripleo.2005.05.060
- 2004. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scandinavian Journal of Gastroenterology. 39: 1088-1094.
- 2004. Femoral and whole-body bone mineral density in middle-aged and older Norwegian men and women: suitability of the reference values. Osteoporosis International. 15: 525-534.
- 2004. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scandinavian Journal of Immunology. 59: 592-599.
- 2004. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren's syndrome with a special 2 emphasis on BAFF. Arthritis and Rheumatism. 50: S578-S578.
- 2004. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjögren's syndrome with a special emphasis on BAFF. Journal of Clinical Immunology. 24: 600-611.
- 2003. A prospective study of sicca symptoms in patients with rheumatoid arthritis. Arthritis Care &Research. 49: 187-192.
- 2003. Seal oil compared to soy oil in patients with inflammatory bowel disease. Gastroenterology. 124: 67-67.
- 2003. Immunoglobulin G and A antibody responses to Bacteroides forsythus and Prevotella intermedia in sera and synovial fluids of arthritis patients. Clinical and Laboratory Immunology. 10: 1043-1050.
- 2003. Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Laboratory Investigation. 83: 1839-1848.
- 2003. Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Laboratory Investigation. 83: 1839-1848.
- 2002. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids. 27: 935-940.
- 2002. Sjögren's syndrome in an out-patient clinic: Classification of patients according to the preliminary European criteria and the proposed modified European criteria. Rheumatology. 41: 301-304.
- 2002. Immunoglobulin G Fc-receptor (FcGammaR) IIA, IIIA and IIIB polymorphisms related to disease severity in rheumatoid arthritis. Journal of Rheumatology. 29: 1135-1140.
- 2002. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids. 37: 935-940.
- 2002. Leucocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study. Scandinavian Journal of Rheumatology. 31: 351-354.
- 1999. Immunoglobulin G, Fc-receptor IIA and IIB plymorphisms related to disease severity in rheumatoid arthritis. Arthritis and Rheumatism. 42: 1045-Abstract.
- 1999. Seasonal variations in activity of systemic lupus erythematosus in a subarctic region. Lupus. 8: 269-273.
- 1999. Complement activation in patients with systemic lupus erythematosus without nephritis. Rhematology Int. 38: 933-940.
- 1998. Calprotectin in inflammatory rheumatic disease - summary of thesis. Scandinavian Journal of Rheumatology. 27: 87-87.
- 1996. Pristane-Induced Arthritis in Rats. A New Model for Rheumatoid Arthritis with a Chronic Disease Course Influenced by Both Major Histocompatibility Complex and Non-Major Histocompatibility Complex Genes. American Journal of Pathology. 149: 1675-1683.
- 1994. Sj@øgren's syndrome in inflammatory rheumatic diseases: Analysis of the leukocyte protein calprotectin in plasma and saliva. Scandinavian Journal of Rheumatology. 23: 114-118.
- 1994. Sj@øgren's syndrome in inflammatory rheumatic diseases; Analysis of the leukocyte protein calprotectin in plasma and saliva. Scandinavian Journal of Rheumatology. 23: 114-118.
- 1994. Sj@øgren's syndrome in inflammatory rheumatic diseases: Analysis of the leukocyte protein calprotein in plasma and saliva. Scandinavian Journal of Rheumatology. 23: 114-118.
- 1994. Sj@øgren's syndrome in inflammatory rheumatic diseases; Analysis of the leukocyte protein calprotectin in plasma and saliva. Scandinavian Journal of Rheumatology. 23: 114-118.
- 1994. Sj@øgren's syndrome in inflammatory rheumatic diseases: Analysis of the leukocyte protein calprotectin in plasma and saliva. Scandinavian Journal of Rheumatology. 23: 114-118.
- 1994. Use of a sicca symptoms questionnaire for the identification of patients with Sj@øgren's syndrome in a heterogenous hospital population with various rheumatic diseases. Clinical and Experimental Rheumatology. 12: 649-652.
- 1994. Use of a sicca symptoms questionnaire for the identification of patients with Sj@øgren's syndrome in a heterogeneous hospital population with various rheumatic diseases. Clinical and Experimental Rheumatology. 12: 649-652.
- 1994. Use of a sicca symptoms questionaire for the identification of patients with Sj@øgren's syndrome in a heterogenous hospital population with various rheumatic diseases. Clinical and Experimental Rheumatology. 12: 649-652.
- 1994. Use of a sicca symptoms questionaire for the identification of patients with Sj@øgren's syndrome in a heterogenous hospital population with various rheumatic diseases. Clinical and Experimental Rheumatology. 12: 649-652.
- 1994. Use of a sicca symptoms questionnaire for the identification of patients with Sj@øgren's syndrome in a heterogeneous hospital population with various rheumatic diseases. Clinical and Experimental Rheumatology. 12: 649-652.
- 1994. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. Journal of Rheumatology. 21: 733-738.
- 1994. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. Journal of Rheumatology. 21: 733-738.
- 1994. Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scandinavian Journal of Immunology. 40: 675-680.
- 1994. Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scandinavian Journal of Immunology. 40: 675-680.
- 1993. Calprotectin in patients with systemec lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus. 2: 47-50.
- 1993. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus. 2: 47-50.
- 1993. Cancer in association with polymyalgia rheumatica and temporal arteritis. Journal of Rheumatology. 20: 135-139.
- 1993. Cancer in association with polymyalgia rheumatica and temporal arteritis. Journal of Rheumatology. 20: 1335-1339.
- 1992. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. Journal of Rheumatology. 19: 859-862.
- 1992. Morning stiffness and nighttime pain in ankylosing spondylitis. A comparison between entericcoated and plain naproxen tablets. European Journal of Rheumatology and Inflammation. 12: 37-42.
Reports and theses
- 2010. 33 Scandinavian Congress of Rheumatology Abstract Supplement. Scandinavian Journal of Rheumatology. Supplement. 39: 124. 45 pages.
- 1996. Calprotectin in inflammatory rheumatic diseases. Clinical and experimental studies. Dr.med.. -. Medical Department B, and Broegelmann Resaerch Laboratory for Microbiology, University of Bergen, Bergen. 1 pages.
Book sections
- 2007. Immunologi og revmatologi. Kapittel 11, pages 98-116. In:
- 2007. Immunologisk forskning i Bergen, Broegelmanns Forskningslaboratorim 1957-2007. 184 pages. ISBN: 978-82-7128-434-3.
- 2005. Serum CCL2, CCL11, and EGF as biomarkers in the spondylarthropaties. Serum CCL2, CCL11, and EGF as biomarkers in the spondylarthropaties., pages 11-14. In:
- 2005. 5th joint meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR). San Juan (Puerto Rico), October 21-25, 2004. 177 pages. ISBN: 88-7587-127-2.
- 1994. Calprotectin in chronically inflamed salivary glands and saliva. 549-551. In:
- 1994. Sj@øgren's syndrome - state of the art.
- 1994. Calprotein in chronically inflamed salivary glands and saliva. 549-551. In:
- 1994. Sj@øgren's syndrome - state of the art.
More information in national current research information system (CRIStin)